Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow EXEL
Exelixis, Inc. (EXEL) EV/Sales
As of 16 October 2026, Exelixis, Inc. (EXEL) trades at a EV/Sales of 6.1×. Over the past ten years it has ranged from 2.0× (October 2022) to 51.3× (August 2015); the current reading is higher than 58% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | 18.53% |
| FY2024 | 4.0× | 8.90% |
| FY2023 | 3.6× | 47.78% |
| FY2022 | 2.5× | (18.29%) |
| FY2021 | 3.0× | (40.69%) |
| FY2020 | 5.1× | 8.91% |
| FY2019 | 4.7× | (23.28%) |
| FY2018 | 6.1× | (68.98%) |
| FY2017 | 19.5× | 11.65% |
| FY2016 | 17.5× | (54.52%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.3× | 21.17% |
| Mar 2026 | 4.3× | (7.19%) |
| Dec 2025 | 4.7× | 5.90% |
| Sep 2025 | 4.4× | (12.31%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| EXEL Exelixis, Inc. | 6.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| INSM Insmed, Inc. compare | 18.1× |
| BBIO BridgeBio Pharma, Inc. compare | 19.9× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)